Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Omeros Corporation (NASDAQ: ... Drug Application (IND) to evaluate OMS824 in Huntington,s ... and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase ... the brain linked to a wide range of ... schizophrenia. OMS824 has shown promising results in animal ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE ( Europe ) approved ... Centre in Scotland , which boasts ... SynCardia temporary Total Artificial Heart powered by the ... Bodyworks Exhibition, one of the most advanced exhibitions of ...
(Date:5/23/2013)... International Corporation (NASDAQ: PRXL ) announced today ... Conference in New York.  James Winschel, Sr. ... be making a presentation on PAREXEL and discussing business ... A live webcast of the presentation will ... at www.PAREXEL.com in the Upcoming Events portion ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2
... Surgery Foundation Announces Speakers, Moderators and Panelists for 2nd International Symposium on MR-Guided Focused ... CHARLOTTESVILLE, Va. , June ... to speak at the 2nd International Symposium for MR-guided Focused Ultrasound, which will be ... , , , ...
... , SANTA BARBARA, Calif. , June 25 ... Diabetes Research Institute (Sansum) announced today the achievement of a milestone ... Foundation (JDRF). , , ... The world,s most flexible artificial pancreas system platform, currently being used ...
Cached Medicine Technology:Leading Experts to Speak at Focused Ultrasound Symposium 2Leading Experts to Speak at Focused Ultrasound Symposium 3Leading Experts to Speak at Focused Ultrasound Symposium 4Leading Experts to Speak at Focused Ultrasound Symposium 5Leading Experts to Speak at Focused Ultrasound Symposium 6JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 2JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 3JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 4JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 5JDRF Reaches Milestone in Artificial Pancreas Project in Partnership with UC Santa Barbara and Sansum Diabetes Research Institute 6
(Date:5/23/2013)... Myers, FL (PRWEB) May 23, 2013 On ... prediction in the midst of growing numbers of H7N9 cases ... UV-Aid, Predict H7N9 Bird Flu Cases Will Subside in Northern ... May 13th no new cases have been reported. , ... the flu is as predictable as flowers budding in the ...
(Date:5/23/2013)... 23, 2013 EnvirOasis, the leader in ... ESCO market is pleased to announce its new line ... LED products. EnvirOasis has been a market leader ... retrofit kits and has recently brought to market a ... Emitting Diode) is energy efficient lighting technology which produces ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- Teen ... among Hispanic teens, according to a new government report. ... 19 dropped by nearly one half from 1991 to 2011 ... 31 births for every 1,000. From 2007 to 2011, ... from 41.5 to about 31. During that time, rates ...
(Date:5/23/2013)... Chinese and U.S. scientists have used virus isolated from ... to determine whether the virus could infect and be ... mammalian model in influenza research, and efficient transmission of ... how well the same process might occur in people. ... Institute of Allergy and Infectious Diseases, part of the ...
(Date:5/23/2013)... Netsmart today announced it is ranked ... information technology (HIT) providers for 2013. , The HCI 100 ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is up ... growth is largely due to our commitment to helping organizations ... where resources are scarce, the demand for care is unprecedented ...
Breaking Medicine News(10 mins):Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2
... with God, affects medical choices, study finds , FRIDAY, Dec. 18 ... cancer could be just as important as taking care of their ... what was important to them at the end of their lives, ... being at peace with God, the study found. , "Medicine ...
... ... the nostrils help deliver scent molecules into the nose to the olfactory bulb, where ... From there, they are forwarded to areas of the central nervous system that mediate ... ...
... ... used across a range of enterprise activities , ... Washington, D.C. (PRWEB) December 18, 2009 -- Applied Predictive Technologies ... in the world, has signed an agreement to license APT,s Test & Learn Management System. ...
... Make your ... certificates and his own name-brand prescription-strength line of skincare products for Christmas. ... Denver, CO (PRWEB) December 17, ... your shopping done! Online gift certificates are now available at www.ravalmd.com and ...
... , , NEW YORK, Dec. 17 The Hebrew University ... Tropical Diseases has received a $5 million grant from the ... The project will be led by Professor Alon Warburg, ... and will include experts from Hebrew University,s Robert H. Smith ...
... , ... , EDF calls for dirty heating oil phase out by 2020 ... of the city,s heating oil soot pollution is created by burning the dirtiest ... City, according to a new report released today by ...
Cached Medicine News:Health News:Spiritual Needs Rank High as Death From Cancer Nears 2Health News:Spiritual Needs Rank High as Death From Cancer Nears 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 2Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 3Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 4Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 5Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 6Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 7Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 8Health News:Adoodle Announces New Advisory Board and Readies the Launch of the New NOXO Behavioral Modification Products 9Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 2Health News:Banfield, The Pet Hospital Signs Agreement to License APT's Test & Learn Management System 3Health News:Streamline Your Holiday Shopping With Online Savings At Ravalmd.com 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 2Health News:Bill & Melinda Gates Foundation Grants $5 Million For Infectious Disease Research At The Hebrew University Of Jerusalem 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 2Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 3Health News:9,000 NYC Buildings Burning Dirty Heating Oil Identified in New Report 4
... new EndoEYE Flexible Video Cystoscope from Olympus ... technology. By marrying proprietary video chip technology ... is now providing a flexible video cystoscope ... of a rigid rod lens system. As ...
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... TherMatrx® Dose Optimized Thermotherapy™ is ... designed for in-office treatment of benign ... most widely used in-office BPH thermotherapy ... surgical solutions for BPH, TherMatrx does ...
... uses Cooled ThermoTherapy® (transurethral microwave ... targeted microwave energy deep into ... necrosis for durable clinical outcomes. ... monitors urethral and rectal temperatures ...
Medicine Products: